ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics" or the
Company") (NYSE MKT: IMUC), a biotechnology company focused on the
development of novel immune-based cancer therapies, announced the
allowance of a Japanese patent relating to a technology for the
treatment of brain cancer for which the Company holds an exclusive,
worldwide license. The patent covers the treatment of brain cancer with
a combination of a dendritic cell based vaccine combined either before
or concurrently with the administration of chemotherapy. The Company
believes that in the treatment of cancer, particularly cancers of the
central nervous system such as glioblastoma multiforme (GBM), a dual
therapeutic approach that includes the administration of a dendritic
cell-based cancer vaccine combined with a regimen of chemotherapy could
substantially enhance the clinical efficacy of treatment.
"The strengthening of our world-wide intellectual property protection
for the treatment and detection of cancers further supports our
developmental efforts and enhances our ability to license or partner our
immunotherapeutic platforms," said Manish Singh, Ph.D. President and CEO
of ImmunoCellular Therapeutics. "It is with this in mind that we
continue to pursue opportunities to solidify our intellectual property
on a global scale."
Air pollution linked to head and neck cancer risk